Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc (AMLX) Historical Volatility
AMLX's 30 day historical volatility is 52.42%, in the 28th percentile of readings over the past year. This is a low percentile, meaning Amylyx Pharmaceuticals Inc shares have been calmer than usual. AMLX's 30 day implied volatility sits at 70.33%, with an IV Rank of 34.92%, leaving IV 17.91 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking AMLX historical volatility helps you see how much Amylyx Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AMLX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AMLX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AMLX's 30 day historical volatility, or AMLX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AMLX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →